2 recruiting, 1 suspended. 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Suspended 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Progressive Glioblastoma: new trials by email Literature Review of Progressive Glioblastoma trials Research Report on Progressive Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Mayo Clinic | 36 | 2026-08-03 | 2026-10-30 |
| Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma Aminolevulinic Acid Intravenous Formulation SONALA-001, Biospecimen Collection, Computed Tomography - Progressive Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Recruiting | Mayo Clinic | 8 | 2025-08-14 | 2026-08-25 |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 184 | 2024-11-08 | 2026-11-03 |
Glioblastoma (3) · Astrocytoma (1) · Gliosarcoma (1)
Glioma (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neoplasms, Neuroepithelial (3) · Neuroectodermal Tumors (3) · Astrocytoma (2)
Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · Surgical Procedures, Operative (2) · Aminolevulinic Acid (1) · Biopsy (1) · Disulfides (1) · Immunoglobulin G (1) · Lomustine (1) · Nivolumab (1) · pembrolizumab (1) · relatlimab (1)
Mayo Clinic (2) · National Cancer Institute (NCI) (1)
United States (3)
Jian L Campian, MD, PhD (1) · Michael Lim (1) · Terence C. Burns, MD, PhD (1)
R44CA275508 (1), U10CA180821 (1)